Karyopharm Therapeutics (NASDAQ:KPTI) has been assigned a $22.00 price target by investment analysts at Robert W. Baird in a report released on Thursday, March 15th. The firm presently has a “buy” rating on the stock. Robert W. Baird’s price objective points to a potential upside of 76.28% from the stock’s current price.
Several other equities analysts have also commented on KPTI. ValuEngine raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 8th. Canaccord Genuity increased their price target on shares of Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, March 12th. BidaskClub raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 9th. Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $20.10.
KPTI stock traded down $0.52 during mid-day trading on Thursday, reaching $12.48. 500,935 shares of the stock traded hands, compared to its average volume of 500,979. The stock has a market capitalization of $645.49, a price-to-earnings ratio of -4.44 and a beta of 3.61. Karyopharm Therapeutics has a one year low of $7.48 and a one year high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.14). The firm had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $2.26 million. During the same quarter in the previous year, the firm posted ($0.65) EPS. The company’s revenue was up 3163.8% on a year-over-year basis. equities research analysts forecast that Karyopharm Therapeutics will post -2.83 earnings per share for the current fiscal year.
In related news, insider Sharon Shacham sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $10.08, for a total transaction of $100,800.00. Following the completion of the sale, the insider now owns 723,510 shares in the company, valued at $7,292,980.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Christopher Brett Primiano sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.01, for a total value of $37,525.00. The disclosure for this sale can be found here. Insiders have sold a total of 69,000 shares of company stock valued at $928,625 over the last three months. Corporate insiders own 14.71% of the company’s stock.
A number of hedge funds have recently bought and sold shares of KPTI. New York State Common Retirement Fund lifted its stake in Karyopharm Therapeutics by 33.6% during the second quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock worth $255,000 after purchasing an additional 7,099 shares during the last quarter. Northern Trust Corp lifted its stake in Karyopharm Therapeutics by 36.5% during the second quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock worth $3,668,000 after purchasing an additional 108,369 shares during the last quarter. Vanguard Group Inc. lifted its stake in Karyopharm Therapeutics by 31.1% during the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after purchasing an additional 384,658 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Karyopharm Therapeutics by 17.3% during the second quarter. Dimensional Fund Advisors LP now owns 323,671 shares of the company’s stock worth $2,930,000 after purchasing an additional 47,699 shares during the last quarter. Finally, Voya Investment Management LLC lifted its stake in Karyopharm Therapeutics by 42.1% during the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.
WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/karyopharm-therapeutics-kpti-given-a-22-00-price-target-at-robert-w-baird.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.